Cutler
Whitely
Biotechnology & Emerging Technologies | Commercial Strategy, Venture Building & National Security | Former Professional Snowboarder
About
I started at community college and went on to compete professionally on the World Snowboard Tour. It wasn’t the conventional path into biotechnology, but it shaped how I approach complex challenges: with discipline, resilience, and a willingness to pursue opportunities beyond the expected path.
My career began in oncology drug discovery at Novartis, where I developed a foundation in scientific research before moving into business development, commercial strategy, and venture building. Since then, I’ve focused on translating promising technologies into commercial opportunities—connecting scientific innovation with strategic partnerships, market opportunities, and pathways to commercialization.
Along the way, I led a team recognized with Ipsen’s First-in-Class Award through Nucleate for its work advancing an innovative therapeutic platform.
Today, I serve as Business Program Manager at Modulation Therapeutics, bringing together scientific understanding and business strategy to support the development and commercialization of biotechnology innovations. My broader experience spans biotechnology, medtech, early-stage ventures, and initiatives strengthening the life sciences innovation ecosystem.
Beyond my operating work, I’m increasingly engaged in the intersection of emerging technologies, economic competitiveness, and public policy. Through industry discussions and initiatives including Builds Bio+, I’ve contributed to conversations around biotechnology commercialization, venture formation, innovation infrastructure, and the conditions needed to translate American scientific leadership into economic and strategic advantage.
I hold an MBA from Columbia Business School and a master’s in biotechnology and engineering from Brown University.
My interests extend across biotechnology, deep tech, and critical technologies, particularly where commercial innovation intersects with economic and national security. I believe the ability to develop, finance, and scale breakthrough technologies is increasingly central to both economic growth and national competitiveness.
I’m always interested in connecting with founders, investors, industry executives, and public-sector leaders working to turn scientific breakthroughs into enduring companies, strategic capabilities, and meaningful impact.
